Welcome to LookChem.com Sign In|Join Free

CAS

  • or

912545-10-9

Post Buying Request

912545-10-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

912545-10-9 Usage

General Description

2,4-bis(benzyloxy)-5-bromobenzoic acid is a chemical compound with the molecular formula C21H17BrO4. It is a white or off-white powder that is insoluble in water and soluble in organic solvents. 2,4-bis(benzyloxy)-5-bromobenzoic acid is used in organic synthesis and as a building block for the preparation of various pharmaceuticals and agrochemicals. It is also used as an intermediate in the production of dyes and pigments. The presence of the bromine atom makes this compound reactive in a variety of chemical reactions, making it a versatile building block for the synthesis of complex organic molecules.

Check Digit Verification of cas no

The CAS Registry Mumber 912545-10-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,2,5,4 and 5 respectively; the second part has 2 digits, 1 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 912545-10:
(8*9)+(7*1)+(6*2)+(5*5)+(4*4)+(3*5)+(2*1)+(1*0)=149
149 % 10 = 9
So 912545-10-9 is a valid CAS Registry Number.

912545-10-9Relevant articles and documents

Novel Tetrahydropyrido[4,3-d]pyrimidines as Potent Inhibitors of Chaperone Heat Shock Protein 90

Jiang, Fen,Wang, Hui-Jie,Jin, Yu-Hui,Zhang, Qiong,Wang, Zhi-Hui,Jia, Jian-Min,Liu, Fang,Wang, Lei,Bao, Qi-Chao,Li, Dong-Dong,You, Qi-Dong,Xu, Xiao-Li

supporting information, p. 10498 - 10519 (2016/12/16)

Heat shock protein 90 (Hsp90) is a potential target for oncology therapeutics. Some inhibitors have shown antitumor effects in clinical trials, spurring the discovery of small molecule Hsp90 inhibitors. Here, we describe the structural optimization studies of a hit compound, tetrahydropyrido[4,3-d]pyrimidine-based Hsp90 inhibitor 15, which exhibits inhibitory activity against Hsp90. A series of analogues were synthesized, and their structure-activity and structure-property relationships were analyzed. These explorations led to the discovery of compound 73, which exhibited potent in vitro activities, good physicochemical properties, favorable ADME properties, and a potent antitumor effect in an HCT116 xenograft model. Furthermore, 73 exhibited no ocular toxicity in a rat retinal damage model, suggesting it is a relatively safe Hsp90 inhibitor. As a promising antitumor agent, 73 was progressed for further preclinical evaluation.

TRIAZOLE DERIVATIVE AS AN HSP 90 INHIBITOR

-

Page/Page column 15-16, (2010/05/13)

5-[4-(2-Methylphenyl)-3-hydroxy-4H-1,2,4-triazol-5-yl]-2,4-dihydroxy-N-methyl-N-butylbenzamide is an HSP90 inhibitor and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.

Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1- ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design

Woodhead, Andrew J.,Angove, Hayley,Carr, Maria G.,Chessari, Gianni,Congreve, Miles,Coyle, Joseph E.,Cosme, Jose,Graham, Brent,Day, Philip J.,Downham, Robert,Fazal, Lynsey,Feltell, Ruth,Figueroa, Eva,Frederickson, Martyn,Lewis, Jonathan,McMenamin, Rachel,Murray, Christopher W.,O'Brien, M. Alistair,Parra, Lina,Patel, Sahil,Phillips, Theresa,Rees, David C.,Rich, Sharna,Smith, Donna-Michelle,Trewartha, Gary,Vinkovic, Mladen,Williams, Brian,Woolford, Alison J.-A.

supporting information; experimental part, p. 5956 - 5969 (2010/11/04)

Inhibitors of the molecular chaperone heat shock protein 90 (Hsp90) are currently generating significant interest in clinical development as potential treatments for cancer. In a preceding publication (DOI: 10.1021/jm100059d) we describe Astex's approach to screening fragments against Hsp90 and the subsequent optimization of two hits into leads with inhibitory activities in the low nanomolar range. This paper describes the structure guided optimization of the 2,4-dihydroxybenzamide lead molecule 1 and details some of the drug discovery strategies employed in the identification of AT13387 (35), which has progressed through preclinical development and is currently being tested in man.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 912545-10-9